BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 20, 2007
 |  BioCentury  |  Product Development

Trapping CAPS

The initial indication for which Regeneron Pharmaceuticals Inc. hopes to market its first product may be small, but the company believes it has learned a lot from the experience of developing rilonacept IL-1 Trap that will be useful for larger indications and other compounds. To wit: it's easier to target diseases that are driven by a specific molecular defect. While this may sound obvious, it's all too often forgotten in the course of R&D.

Last week, FDA accepted for filing and granted Priority Review to a BLA for rilonacept to treat CIAS1-associated periodic syndromes (CAPS).

REGN's Traps are fusion proteins that combine distinct receptor components and the Fc region of an IgG antibody. Traps are designed to attach to and neutralize circulating target ligands before they...

Read the full 620 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >